april
may
period
sar
outbreak
taipei
adult
patient
admit
emerg
depart
nation
taiwan
univers
hospit
met
clinic
case
definit
probabl
sar
includ
studi
physician
sar
research
group
nation
taiwan
univers
hospit
made
diagnosi
patient
thorough
evalu
travel
contact
histori
symptom
laboratori
data
includ
lymphopenia
thrombocytopenia
elev
level
lactat
dehydrogenas
creatin
kinas
pneumon
patch
chest
xray
first
day
fever
defin
day
ill
serolog
test
indirect
immunofluoresc
assay
perform
serum
specimen
collect
day
onset
confirm
sarscov
infect
patient
four
patient
least
two
posit
realtim
rtpcr
result
therefor
case
probabl
sar
studi
confirm
laboratori
test
patient
consent
saliva
throat
wash
gargl
ml
normal
salin
collect
airborn
isol
room
accord
guidelin
aerosolgener
procedur
sampl
transfer
biosafeti
level
laboratori
store
use
thaw
ml
throat
wash
centrifug
x
g
min
separ
supernat
mucouscel
pellet
four
millilit
supernat
collect
throat
wash
supernat
remain
portion
contain
mucouscel
pellet
treat
equal
volum
nacetyllcystein
room
temperatur
min
centrifug
x
g
min
separ
cell
pellet
supernat
ml
collect
treat
supernat
throat
wash
instead
extens
wash
potenti
contagi
cell
pellet
kept
remain
ml
cellular
fraction
throat
wash
equal
amount
supernat
treat
supernat
cellular
fraction
subject
viral
rna
extract
aliquot
saliva
equal
volum
x
phosphatebuff
salin
pb
ad
also
subject
viral
rna
extract
viral
rna
isol
aliquot
saliva
differ
fraction
throat
wash
probabl
sar
patient
healthi
control
use
qiaamp
viral
rna
mini
kit
qiagen
hilden
germani
laboratori
viral
rna
also
isol
cultur
supernat
sarscov
isol
human
coronaviru
strain
human
enter
coronaviru
dalla
strain
american
type
cultur
collect
manassa
va
assay
use
forward
revers
primer
fluorogen
probe
taqman
assay
design
appli
biosystem
foster
citi
ca
match
region
within
previous
describ
region
also
complet
conserv
differ
isol
sarscov
figur
sequenc
forward
primer
revers
primer
probe
genom
posit
urbani
strain
posit
posit
respect
product
cover
region
gener
use
primer
superscript
ii
onestep
rtpcr
system
invitrogen
san
diego
ca
rna
templat
deriv
sarscov
strain
sequenc
primer
genom
posit
posit
respect
rtpcr
condit
min
min
follow
cycl
min
min
product
subsequ
clone
ta
clone
vector
invitrogen
san
diego
ca
gener
construct
figur
vitro
transcrib
rna
purifi
quantifi
determin
copi
number
rna
describ
previous
aliquot
rna
isol
clinic
sampl
known
amount
vitro
transcrib
rna
million
copi
subject
realtim
rtpcr
use
primer
probe
taqman
onestep
realtim
rtpcr
master
mix
reagent
kit
appli
biosystem
amplif
condit
min
min
follow
cycl
min
abi
prism
sequenc
detector
use
analyz
emit
fluoresc
amplif
posit
result
defin
cycl
number
ct
valu
requir
reach
threshold
describ
previous
precaut
pcr
follow
avoid
contamin
sinc
rna
eluat
deriv
throat
wash
supernat
use
reaction
number
sarscov
rna
copi
per
reaction
divid
x
multipli
determin
rna
copi
per
millilit
sensit
assay
copi
rna
per
reaction
correspond
copi
per
millilit
throat
wash
use
follow
formula
calcul
copi
number
sarscov
rna
differ
compon
includ
supernat
mucusassoci
cellassoci
c
compon
throat
wash
start
volum
fraction
experi
number
rna
copi
compon
equal
amount
copiesml
supernat
time
ml
supernat
x
ml
sinc
treatment
mucuscel
pellet
nacetyllcystein
presum
releas
sarscov
mucu
increas
volum
twofold
ml
ml
copi
number
compon
equal
amount
treat
supernat
copiesml
time
ml
minu
origin
untreat
supernat
ml
treat
supernat
x
ml
supernat
x
ml
copi
number
c
compon
equal
amount
cellular
fraction
copiesml
time
volum
cell
pellet
c
cellular
fraction
x
volum
cell
pellet
ml
take
patient
exampl
copi
x
copi
x
x
c
copi
x
amount
sarscov
rna
cellfre
compon
equal
amount
compon
plu
compon
copi
correspond
total
sarscov
rna
ml
throat
wash
cellassoci
compon
copi
correspond
total
tabl
aliquot
cellular
fraction
throat
wash
patient
six
healthi
control
fix
onto
teflonco
slide
subject
previous
describ
immunofluoresc
assay
first
antibodi
serum
rabbit
immun
recombin
nucleocapsid
protein
sarscov
prepar
pj
chen
secondari
antibodi
fitcconjug
goat
antirabbit
immunoglobulin
g
pierc
biotechnolog
rockford
il
regress
analysi
perform
examin
correl
sampl
day
amount
sarscov
rna
throat
wash
saliva
correl
amount
throat
wash
saliva
softwar
spss
base
spss
inc
chicago
il
demograph
clinic
inform
patient
summar
tabl
viral
rna
extract
saliva
supernat
throat
wash
subject
quantit
realtim
rtpcr
assay
use
primer
probe
within
highli
conserv
region
figur
known
amount
vitro
transcrib
rna
cover
region
use
standard
quantif
shown
figur
linear
curv
observ
input
rna
increas
million
copi
per
reaction
posit
signal
detect
reaction
contain
rna
templat
deriv
sarscov
taiwanes
strain
healthi
control
two
human
coronavirus
strain
human
enter
coronaviru
dalla
strain
reaction
contain
rna
data
shown
result
realtim
rtpcr
assay
throat
wash
saliva
summar
tabl
sampl
day
patient
vari
day
day
onset
fever
median
day
sarscov
rna
readili
detect
throat
wash
patient
amount
sarscov
rna
throat
wash
x
x
copi
per
ml
median
x
copiesml
sarscov
rna
also
detect
saliva
avail
specimen
amount
sarscov
rna
saliva
x
x
copi
per
ml
median
x
copiesml
amount
sarscov
rna
throat
wash
saliva
correl
sampl
day
simpl
linear
regress
coeffici
correl
r
respect
underscor
complex
cours
virushost
interact
amount
sarscov
rna
saliva
greater
throat
wash
everi
patient
type
specimen
avail
linear
relationship
exist
amount
sarscov
saliva
throat
wash
simpl
linear
regress
r
p
suggest
prove
could
origin
common
sourc
respiratori
tract
investig
whether
sarscov
also
present
cellular
compon
throat
wash
carri
fraction
experi
examin
amount
sarscov
rna
differ
compon
shown
tabl
sarscov
rna
detect
cellassoci
compon
throat
wash
specimen
examin
rang
viral
load
copi
per
ml
throat
wash
sarscov
rna
throat
wash
present
cellassoci
compon
greater
proport
sarscov
rna
present
cellfre
compon
find
suggest
sarscov
releas
effici
possibl
viru
releas
cell
thaw
unlik
sinc
fraction
experi
perform
aliquot
sampl
without
prior
freez
thaw
show
similar
result
exampl
percentag
cellassoci
cellfre
compon
aliquot
perform
without
freez
respect
similar
result
anoth
aliquot
perform
freez
thaw
tabl
electron
microscop
studi
shown
sarscov
particl
desquam
cell
bronchoalveolar
lavag
lung
tissu
lower
respiratori
tract
detect
sarscov
rna
cellassoci
compon
throat
wash
suggest
sarscov
also
replic
upper
respiratori
tract
explor
possibl
prepar
spot
slide
cellular
fraction
throat
wash
examin
indirect
immunofluoresc
assay
use
polyclon
serum
rabbit
immun
recombin
nucleocapsid
protein
sarscov
use
epitheli
cell
prepar
two
randomli
chosen
specimen
postimmun
serum
preimmun
serum
react
epitheli
cell
speckl
pattern
figur
classif
cell
epitheli
cell
support
size
morpholog
featur
light
microscop
figur
background
signal
seen
cell
prepar
healthi
control
figur
find
indic
sarscov
replic
epitheli
cell
upper
respiratori
tract
cell
use
antigen
detect
assay
report
larg
amount
sarscov
rna
throat
wash
saliva
probabl
sar
casepati
find
support
possibl
sarscov
transmit
oral
droplet
coronavirus
known
replic
epitheli
cell
respiratori
enter
tract
bud
pregolgi
compart
viru
particl
releas
exocytosislik
process
apic
basolater
surfac
apic
releas
like
facilit
spread
viru
respiratori
enter
tract
wherea
basolater
releas
facilit
system
spread
find
sarscov
detect
cell
deriv
throat
wash
immunofluoresc
assay
sarscov
throat
wash
present
cellfre
compon
suggest
replic
epitheli
cell
sarscov
releas
effici
accumul
oropharynx
oral
caviti
may
contribut
transmiss
oral
droplet
practic
droplet
contact
precaut
prevent
nosocomi
transmiss
sar
among
healthcar
worker
howev
cluster
sar
case
report
among
appar
protect
healthcar
worker
aerosolgener
procedur
perform
sar
patient
find
led
controversi
hypothesi
airborn
transmiss
sar
small
particl
spread
air
substanti
proport
sarscov
throat
wash
present
cellfre
form
find
offer
mechanist
explan
possibl
airborn
transmiss
sar
three
type
specimen
upper
respiratori
tract
nasopharyng
aspir
nasopharyng
swab
oropharyng
swab
recommend
detect
sarscov
howev
rtpcr
perform
nasopharyng
aspir
sar
patient
posit
rate
day
day
day
recent
studi
use
nasopharyng
aspir
report
posit
rate
mean
day
studi
report
sarscov
rna
detect
throat
wash
saliva
specimen
examin
averag
sampl
day
rang
day
furthermor
specimen
throat
wash
four
studi
particip
came
emerg
depart
design
sar
screen
site
taipei
sar
outbreak
collect
radiograph
evid
pneumonia
respiratori
distress
syndrom
observ
tabl
knowledg
report
first
show
sarscov
could
detect
probabl
sar
patient
lung
lesion
develop
high
sarscov
detect
rate
studi
contrast
report
previous
use
nasopharyng
aspir
one
possibl
sarscov
present
oropharynx
oral
caviti
nasopharynx
spite
differ
dilut
factor
exampl
ml
normal
salin
throat
wash
ml
nasopharyng
aspir
none
saliva
amount
sarscov
rna
throat
wash
saliva
studi
x
x
copi
per
ml
rang
previous
report
nasopharyng
specimen
copiesml
mutual
nonexclus
possibl
respiratori
secret
mucu
cell
remov
respiratori
tract
throat
wash
nasopharyng
aspir
nasopharyng
swab
oropharyng
swab
regardless
reason
sarscov
also
detect
throat
wash
nine
sar
patient
previou
report
suggest
need
evalu
benefit
collect
throat
wash
diagnos
sar
knowledg
report
first
demonstr
possibl
devis
sarscov
antigen
detect
assay
use
cell
deriv
throat
wash
sinc
small
number
patient
examin
futur
studi
patient
control
requir
develop
use
diagnost
test
technic
throat
wash
saliva
easier
collect
compar
collect
current
recommend
respiratori
specimen
addit
obtain
without
close
contact
patient
healthcar
worker
thu
reduc
risk
infect
healthcar
worker
anoth
commonli
obtain
sampl
sputum
howev
rare
avail
earli
stage
infect
virtual
cough
dri
cough
present
featur
togeth
high
detect
rate
earli
stage
develop
lung
lesion
suggest
throat
wash
saliva
ideal
specimen
earli
diagnosi
sar
includ
guidelin
sampl
collect
sar
diagnosi
studi
longitudin
collect
throat
wash
saliva
specimen
larger
number
sar
patient
would
help
determin
onset
durat
infect
extent
infect
patient
superspread
respons
antivir
agent
